Neurotechnology

Precision Neuroscience

Medium1/4 relationships sourcedProfile verified Jul 22, 2026
OverviewSourcesM&A fitRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

Precision Neuroscience functions as a regional institution within Neurotechnology, backed by 43% sourcing coverage, with a stable competitive position.

  • Maintains 4 mapped relationships across the graph
  • 43% sourcing coverage across sourced relationships
  • Tracked as regional institution within the Neurotechnology category

Executive Snapshot

Strategic Role
Regional Institution
Sourcing Coverage
43%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Moderate
Strategic Momentum
Insufficient Data

Coverage

Mapped Relationships
4
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Positioned as a potential first-mover to commercialization given its less invasive, already-cleared deviceTargeting a share of an estimated $2 billion near-term BCI market

Top Risks

Commercialization path from cleared device to durable revenue still unprovenCompetes against far better-funded Neuralink

Critical Dependencies

Continue to Dependency Graph ↓

Developer of the Layer 7 Cortical Interface, a thin-film, minimally invasive brain-computer interface that received FDA 510(k) clearance for intraoperative use of up to 30 days, a major extension from prior hours-long limits. Precision Neuroscience has raised roughly $183 million in total funding, partnered with UChicago Medicine researchers in April 2026 to advance BCI research, and is frequently cited as a contender to reach commercialization milestones ahead of Neuralink and Synchron given its less invasive surgical approach.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

2 sources

⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding Precision Neuroscience — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far

Jan 2021: Founded→Jan 2025: FDA 510(k) clearance for Layer 7 Cortical Interface→Apr 2025: FDA clears Precision Neuroscience's minimally invasive brain-computer interface implant→Apr 2026: Precision Neuroscience partners with UChicago Medicine on BCI research

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

⚡

Precision Neuroscience's Timeline

A sourced, dated history of Precision Neuroscience's key moments — founding to present.

  1. Jan 2021 · Founded

    Precision Neuroscience was founded to develop a minimally invasive, thin-film cortical brain-computer interface.

  2. Jan 2025 · FDA 510(k) clearance for Layer 7 Cortical Interface

    Precision Neuroscience's Layer 7 Cortical Interface received FDA 510(k) clearance, extending permitted clinical use from hours to up to 30 days.